Small Molecule API Market Research Report - Forecast to 2027

Small Molecule API Market Research Report: Information, by Types (Synthetic/Chemical API and Biological API), Application (Cardiovascular, Oncology, Diabetes, Immunological Disorders and others), Manufacturing Method (In-House and Contract) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast To 2027

ID: MRFR/Pharma/0279-CR | February 2021 | Region: Global | 109 pages

Small Molecule API Market overview 


Small molecules are an organic component with low molecular weight. The small molecule API is an active ingredient used in pharmaceuticals and biological procedures. Also, The API can be used as a combination in any finished pharmaceutical product. It is a crucial element in the pharmaceutical industry. The molecule has effective in the treatment, diagnosis and prevention of the disease. The molecular value of the small API is approximately known 900 Daltons. The lower molecular weight of the small API offers quick infusibility features.


Also, the requirement of the small molecular API is high in the pharmaceutical industry. There are plenty of uses of this chemically active ingredient. The effects of the small molecule pharmaceuticals are exceptional. The small molecules are mostly administered orally. The body absorbs this active solution quickly due to its low molecular weight. Due to its versatile uses, the small molecule API market size is expected to grow by 7.0% CAGR. Also, the small molecule API market value will increase by USD 279,687.1 Million in the forecast year 2027. The small-molecule API market trend looks positive till the forecast period. 


Covid analysis 


The outbreak of covid 19 has caused several unexpected twists in the global markets. Low demand and supply chain disruption are the common issues. However, the small molecule drug market has fewer effects. The market growth is stable even during the covid 19. There is a slight decline in the supply and demand disruption in the market. However, the small molecule API manufacturing process is resuming at an exponential pace. There is a massive expansion in the use of small molecule API in the healthcare sector.


Also, the drug development and vaccine research process are increasing the need for the small molecule API market in the pandemic. Further, the new drug developments are the crucial factors for the high growth of the small molecule API in the covid 19 periods. Further, the post covid 19 trends of the small molecule API looks promising. More growth and market expansion opportunities are available for this market. Also, the awareness about this active ingredient is increasing during this period. Therefore, the small molecule API market analysis shows a positive impact. 


Market dynamics 



  • The crucial market drivers 


Cardiovascular, cancer and infectious diseases are increasing at an alarming rate. The small molecule API is a crucial element in drugs development for these diseases. The rising rate of chronic diseases is the crucial demand driving factor for the small molecule API market. The pharmaceutical industry is demanding more of the small molecule component. It enhances the market growth and development in the forecast period.


Secondly, the awareness about the small molecule API is massive in several regions. The rising health consciousness among the customers is raising the demand for the small molecule API. Due to high research and development, the pharmaceuticals industry and the customers are aware of its benefits. It is a crucial aspect that acts as a vital market driver for the global market. Cost is another great advantage in this market. Pharmaceutical small molecule API manufacturing cost per kilogram is less. It is an affordable active ingredient that can be used in the various drug development processes. The Small molecule API manufacturing cost per gram is a crucial driver for this market. 



  • The market growth opportunities 


The small molecule API market has plenty of opportunities as there is new drug development happening every year. As far as the drug development process is increasing the need for small molecule API will also increase. The market has great prospects that will increase the demand as well as the profitability.


The technological advancements in the healthcare sector offer massive growth opportunities for this market. The development of healthcare infrastructure enables more R&D. The increasing rate of research in drug development will result in more utilization of the small molecule API. It will also unveil small molecule pharma capabilities. The companies that provide small molecule API will have higher opportunities in the upcoming years. Therefore, it is expected that the small molecule API market will flourish during the forecasts period. Due to the ongoing developments and awareness, the market will have promising future growth opportunities. 



  • The market restraints 


The wider use of small molecule API enables market expansion. However, with the wide range of use of small molecule the regulation of product usage has increased. There are several stringent regulations by the government regarding small molecule usage. The small molecule API is a chemical product that should be used in the right dosage. The amount of drug usage and the safe use of this active element are crucial in every process. This stringent governmental regulation is a vital factor that restraints market growth. There are both small and large molecules used in the drug development process. The small molecule vs. large molecule proportion and regulations is another factor that restricts the market growth. This product restrain can cause a slight decline in the demand for the small molecule in the forecast period. 



  • The market challenges 


The small molecule API market has plenty of key market players. Moreover, the entry of new market players is causing several challenges in this market. Also, several market players are facing recession and financial issues. It affects the profitability and the overall market expansion rate. The global recession is severely affecting market growth. Also, the economical-recession is disturbing the product demand and supply in the global market. 



  • The cumulative growth analysis 


The small molecule API market will witness a surging demand during the forecast period. The market trends are uniform that will enable exceptional future growth opportunities. The market drivers will intensify in the upcoming years that will result in more market demand. However, some factors can restraint the market growth during the forecast period. The stringent regulation regarding product usage can restrict market growth. Amidst these factors, the growth rate is massive for the small molecule API market. Also, the future growth opportunities of the market look promising. 



  • The value chain analysis 


North America holds the maximum small molecule API market share. The adoption rate of the small molecule element is high in this region. Also, innovation and development in the medical sector are rising in this region. All these aspects contribute to the rapid growth of the small molecule API in North America. Moreover, the prevalence of oncology, cardiovascular and cancer is higher in this region. It provides more growth opportunities for the small molecule API market. 


Market segment


By type 



  • Biological procedures 

  • Chemical process


By application 



  • Ophthalmology

  • Cardiovascular 

  • Metabolic 

  • Dermatology 

  • Respiratory 

  • Urology 

  • Autoimmune disease 

  • Dermatology 

  • Infectious 

  • Immunology 


By product



  • Contract 

  • Captive 


By geography 



  • North America 

  • Asia pacific 

  • Europe 

  • Latin America 

  • Middle East 


Regional analysis 


North America is the largest small molecule API market, shareholder. US, Canada and Mexico are the key players in the North American region. The high investments in the pharmaceutical industry are the major market driving factor in this region. Also, Europe will witness the highest growth rate in the forecast year 2022. The advancement of the pharmaceutical industry is the major factor for high growth in this region. Europe will witness more drug development and research in the forecast year.


Asia Pacific is a region that is witnessing the fastest market growth. The low cost of the small molecule API is driving the market growth in this region. in the upcoming years, Asia pacific will produce new products with these components. The small molecule API market size will grow tremendously in this region during 2027. The Middle East and Latin America are the emerging market. The small molecule API manufacturing process is growing massively during the forecast period. All the regional players will experience a high growth rate and profitability. 


Competitive landscape 


The competition in the small molecule API market is growing higher due to the entry of new market players. During the forecast period, the small molecule API contracting companies are increasing the productions. Also, the key players are creating more product awareness during the forecast year. 


The key players of the small molecule API market are 



  1. Teva Pharmaceuticals

  2. ALLERGAN

  3. BASF SE

  4. Siegfried Holding AG

  5. Sun Pharmaceuticals

  6. Sanofi S.A

  7. Albany Molecular Research Inc

  8. Novartis AG

  9. Albemarle Corporation

  10. Dr Reddy’s Laboratories Ltd

  11. Merck Sharp & Dohme Corp

  12. GlaxoSmithKline plc 

  13. Pfizer Inc.


Recent developments 



  1. The key players of the market are investing more in the large molecule API. It enables new developments and product capabilities. 



  1. The key players of the market are acquiring several pharmaceutical firms to expand the market. 



  1. The key players of the market are establishing new biopharmaceuticals. The new establishment focuses on API sterile and injections. 


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 279,687.1 Million
  CAGR   7.0% (2019-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Applications, Manufacturing
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Albemarle Corporation, Allergan Plc, Aurobindo Pharma, Cambrex Corporation, Dr. Reddy’s Laboratories Ltd, Glaxosmithkline Plc, Lonza, Merck Sharp & Dohme Corp., Mylan N.V., Novartis AG, Pfizer Inc., Siegfried AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
  Key Market Opportunities

  • New drug development
  • The technological advancements in the healthcare sector
  • Ongoing developments and awareness
  •   Key Market Drivers

  • The rising rate of chronic diseases
  • The rising health consciousness among the customers
  • High research and development


  • Frequently Asked Questions (FAQ) :


    small molecule API market size is expected to grow by 7.0% CAGR By 2027

    small molecule API market valuation would be USD 279,687.1 million.

    small molecule API market has segments like diabetes, oncology, cardiovascular, and immunological disorders.

    The segments are in-house manufacturing (Captive) and contract manufacturing (CMO).

    The types included are synthetic/chemical API and biological API.

    1 INTRODUCTION

    1.1 DEFINITION 12

    1.2 SCOPE OF STUDY 12

    1.2.1 RESEARCH OBJECTIVE 12

    1.2.2 ASSUMPTIONS & LIMITATIONS 13

    1.2.2.1 ASSUMPTIONS 13

    1.2.2.2 LIMITATIONS 13

    1.3 MARKET STRUCTURE: 13

    2 RESEARCH METHODOLOGY

    2.1 RESEARCH PROCESS: 14

    2.2 PRIMARY RESEARCH 15

    2.3 SECONDARY RESEARCH: 15

    3 MARKET DYNAMICS

    3.1 DRIVERS 16

    3.1.1 GROWING DEMAND FOR NEWLY DEVELOPED SMALL MOLECULES DRUGS 16

    3.1.2 GROWING TREND OF OUTSOURCING 16

    3.1.3 GROWING PHARMACEUTICAL INDUSTRY IN DEVELOPING NATIONS 17

    3.2 RESTRAINTS 17

    3.2.1 AUSTERITY MEASURES IN EUROPE 17

    3.3 OPPORTUNITIES 17

    3.4 MACROECONOMIC INDICATORS 18

    4 MARKET FACTOR ANALYSIS

    4.1 PORTERS FIVE FORCES MODEL 19

    4.2 BARGAINING POWER OF SUPPLIERS 20

    4.3 BARGAINING POWER OF BUYERS 20

    4.4 THREAT OF NEW ENTRANTS 20

    4.5 THREAT OF SUBSTITUTES 20

    4.6 INTENSITY OF RIVALRY 20

    5 SMALL MOLECULES API, BY TYPE

    5.1 SYNTHETIC/CHEMICAL API 22

    5.2 BIOLOGICAL API 23

    6 SMALL MOLECULE API MARKET, BY APPLICATION

    6.1 CARDIOVASCULAR 27

    6.2 ONCOLOGY 28

    6.3 DIABETES 29

    6.4 IMMUNOLOGICAL DISORDERS 30

    7 SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS

    7.1 IN-HOUSE MANUFACTURING 33

    7.2 CONTRACT MANUFACTURING 34

    7.2.1 INTRODUCTION 34

    8 GLOBAL SMALL MOLECULE API MARKET, BY REGION

    8.1 NORTH AMERICA 39

    SMALL MOLECULES API, BY TYPE

    SMALL MOLECULE API MARKET, BY APPLICATION

    SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS

    8.1.1 INTRODUCTION 40

    8.2 EUROPE 46

    SMALL MOLECULES API, BY TYPE

    SMALL MOLECULE API MARKET, BY APPLICATION

    SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS

    8.2.1 INTRODUCTION 47

    8.3 ASIA-PACIFIC 58

    SMALL MOLECULES API, BY TYPE

    SMALL MOLECULE API MARKET, BY APPLICATION

    SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS

    8.3.1 INTRODUCTION 59

    8.4 MIDDLE EAST & AFRICA 72

    SMALL MOLECULES API, BY TYPE

    SMALL MOLECULE API MARKET, BY APPLICATION

    SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS

    8.4.1 INTRODUCTION 76

    9 COMPETITIVE LANDSCAPE

    9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS 77

    9.1.1 STRATEGIC PARTNERSHIP 78

    9.1.2 MERGER & ACQUISITION 78

    10 COMPANY PROFILE

    10.1 ALBEMARLE CORPORATION 80

    10.1.1 OVERVIEW 80

    10.1.2 PRODUCT OVERVIEW 80

    10.1.3 FINANCIALS 81

    10.1.4 KEY DEVELOPMENTSS 81

    10.2 ALLERGAN PLC 82

    10.2.1 OVERVIEW 82

    10.2.2 PRODUCT OVERVIEW 82

    10.2.3 FINANCIALS 83

    10.2.4 KEY DEVELOPMENTSS 83

    10.3 AUROBINDO PHARMA 84

    10.3.1 OVERVIEW 84

    10.3.2 PRODUCT OVERVIEW 84

    10.3.3 FINANCIALS 85

    10.3.4 STRATEGIES 85

    10.3.5 KEY DEVELOPMENTS 85

    10.4 CAMBREX CORPORATION 86

    10.4.1 OVERVIEW 86

    10.4.2 PRODUCT OVERVIEW 86

    10.4.3 FINANCIALS 87

    10.4.4 KEY DEVELOPMENTS 87

    10.5 DR. REDDY’S LABORATORIES LTD. 88

    10.5.1 OVERVIEW 88

    10.5.2 PRODUCT OVERVIEW 88

    10.5.3 FINANCIALS 89

    10.5.4 KEY DEVELOPMENTS 89

    10.6 GLAXOSMITHKLINE PLC 90

    10.6.1 OVERVIEW 90

    10.6.2 PRODUCT OVERVIEW 90

    10.6.3 FINANCIALS 91

    10.6.4 STRATEGIES 91

    10.6.5 KEY DEVELOPMENTS 92

    10.7 LONZA 92

    10.7.1 OVERVIEW 92

    10.7.2 PRODUCT OVERVIEW 92

    10.7.3 FINANCIALS 93

    10.7.4 STRATEGIES 93

    10.7.5 KEY DEVELOPMENTS 94

    10.8 MERCK SHARP & DOHME CORP. 94

    10.8.1 OVERVIEW 94

    10.8.2 PRODUCT OVERVIEW 95

    10.8.3 FINANCIAL 95

    10.8.4 KEY DEVELOPMENTS 96

    10.9 MYLAN N.V. 96

    10.9.1 OVERVIEW 96

    10.9.2 PRODUCT OVERVIEW 97

    10.9.3 FINANCIALS 97

    10.9.4 KEY DEVELOPMENTS 98

    10.10 NOVARTIS AG 98

    10.10.1 OVERVIEW 98

    10.10.2 PRODUCT OVERVIEW 99

    10.10.3 FINANCIALS 99

    10.10.4 STRATEGIES 99

    10.10.5 DEVELOPMENTS 100

    10.11 PFIZER INC. 100

    10.11.1 OVERVIEW 100

    10.11.2 PRODUCT OVERVIEW 101

    10.11.3 FINANCIALS 101

    10.11.4 KEY DEVELOPMENTS 102

    10.12 SIEGFRIED AG 102

    10.12.1 OVERVIEW 102

    10.12.2 PRODUCT OVERVIEW 102

    10.12.3 FINANCIALS 103

    10.12.4 KEY DEVELOPMENTS 103

    10.13 SUN PHARMACEUTICAL INDUSTRIES LTD. 104

    10.13.1 OVERVIEW 104

    10.13.2 PRODUCT OVERVIEW 104

    10.13.3 FINANCIALS 105

    10.13.4 KEY DEVELOPMENTS 105

    10.14 TEVA PHARMACEUTICAL INDUSTRIES LTD 106

    10.14.1 OVERVIEW 106

    10.14.2 PRODUCT OVERVIEW 106

    10.14.3 FINANCIALS 107

    10.14.4 STRATEGIES 107

    10.14.5 KEY DEVELOPMENTS 108

    11 LIST OF TABLES

    TABLE 1 GLOBAL SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 22

    TABLE 2 GLOBAL SYNTHETIC/CHEMICAL API MARKET, BY REGION, 2020–2027 (USD MILLION) 23

    TABLE 3 GLOBAL BIOLOGICAL API MARKET, BY REGION, 2020–2027 (USD MILLION) 24

    TABLE 4 GLOBAL SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 26

    TABLE 5 GLOBAL SMALL MOLECULE API MARKET: CARDIOVASCULAR, BY REGION, 2020–2027 (USD MILLION) 27

    TABLE 6 GLOBAL SMALL MOLECULE API MARKET: ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 28

    TABLE 7 GLOBAL SMALL MOLECULE API MARKET: DIABETES, BY REGION, 2020–2027 (USD MILLION) 29

    TABLE 8 GLOBAL SMALL MOLECULE API MARKET: IMMUNOLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 30

    TABLE 9 GLOBAL SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 32

    TABLE 10 GLOBAL SMALL MOLECULE API MARKET, BY IN-HOUSE MANUFACTURING, 2020–2027 (USD MILLION) 33

    TABLE 11 GLOBAL SMALL MOLECULE API MARKET, BY CONTRACT MANUFACTURING, 2020–2027 (USD MILLION) 34

    TABLE 12 GLOBAL SMALL MOLECULE API MARKET, BY REGION, 2020–2027 (USD MILLION) 38

    TABLE 13 NORTH AMERICA SMALL MOLECULE API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 39

    TABLE 14 NORTH AMERICA SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 40

    TABLE 15 NORTH AMERICA SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 41

    TABLE 16 NORTH AMERICA SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD, 2020–2027 (USD MILLION) 42

    TABLE 17 US SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 43

    TABLE 18 US SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 44

    TABLE 19 US SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 44

    TABLE 20 CANADA SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 45

    TABLE 21 CANADA SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 45

    TABLE 22 CANADA SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 46

    TABLE 23 EUROPE SMALL MOLECULE API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 47

    TABLE 24 EUROPE SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 48

    TABLE 25 EUROPE SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 49

    TABLE 26 EUROPE SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD, 2020–2027 (USD MILLION) 50

    TABLE 27 GERMANY SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

    TABLE 28 GERMANY SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 51

    TABLE 29 GERMANY SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD, 2020–2027 (USD MILLION) 52

    TABLE 30 FRANCE SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

    TABLE 31 FRANCE SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 53

    TABLE 32 FRANCE SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD, 2020–2027 (USD MILLION) 53

    TABLE 33 UK SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

    TABLE 34 UK SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 54

    TABLE 35 UK SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD, 2020–2027 (USD MILLION) 55

    TABLE 36 ITALY SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

    TABLE 37 ITALY SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 56

    TABLE 38 ITALY SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD, 2020–2027 (USD MILLION) 56

    TABLE 39 SPAIN SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

    TABLE 40 SPAIN SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 57

    TABLE 41 SPAIN SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD, 2020–2027 (USD MILLION) 58

    TABLE 42 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59

    TABLE 43 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

    TABLE 44 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 61

    TABLE 45 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 62

    TABLE 46 JAPAN SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

    TABLE 47 JAPAN SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 63

    TABLE 48 JAPAN SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 64

    TABLE 49 CHINA SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

    TABLE 50 CHINA SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 65

    TABLE 51 CHINA SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 65

    TABLE 52 INDIA SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

    TABLE 53 INDIA SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 66

    TABLE 54 INDIA SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 67

    TABLE 55 SOUTH KOREA SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

    TABLE 56 SOUTH KOREA SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 68

    TABLE 57 SOUTH KOREA SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 69

    TABLE 58 AUSTRALIA SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

    TABLE 59 AUSTRALIA SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 70

    TABLE 60 AUSTRALIA SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 71

    TABLE 61 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY REGION, 2020–2027 (USD MILLION) 72

    TABLE 62 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

    TABLE 63 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 74

    TABLE 64 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS, 2020–2027 (USD MILLION) 75

    12 LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS 14

    FIGURE 2 PORTERS FIVE FORCES MODEL 19

    FIGURE 3 GLOBAL SMALL MOLECULE API MARKET, BY TYPE 22

    FIGURE 4 GLOBAL SMALL MOLECULE API MARKET, BY APPLICATION 26

    FIGURE 5 GLOBAL SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS 32

    FIGURE 6 CONTRACT MANUFACTURING ORGANIZATIONS: MARKET SHARE ANALYSIS (%) 35

    FIGURE 7 GLOBAL SMALL MOLECULE API MARKET, BY REGION 38

    FIGURE 8 NORTH AMERICA SMALL MOLECULE API MARKET, BY COUNTRY (%) 39

    FIGURE 9 NORTH AMERICA SMALL MOLECULE API MARKET, BY TYPE 40

    FIGURE 10 NORTH AMERICA SMALL MOLECULE API MARKET, BY APPLICATION 41

    FIGURE 11 NORTH AMERICA SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD 42

    FIGURE 12 EUROPE SMALL MOLECULE API MARKET, BY COUNTRY (%) 46

    FIGURE 13 EUROPE SMALL MOLECULE API MARKET, BY TYPE 48

    FIGURE 14 EUROPE SMALL MOLECULE API MARKET, BY APPLICATION 49

    FIGURE 15 EUROPE SMALL MOLECULE API MARKET, BY MANUFACTURING METHOD 50

    FIGURE 16 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY COUNTRY (%) 58

    FIGURE 17 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY TYPE 60

    FIGURE 18 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY APPLICATION 61

    FIGURE 19 ASIA-PACIFIC SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS 62

    FIGURE 20 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY COUNTRY (%) 72

    FIGURE 21 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY TYPE 73

    FIGURE 22 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY APPLICATION 74

    FIGURE 23 MIDDLE EAST & AFRICA SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS 75

    FIGURE 24 GLOBAL SMALL MOLECULE API MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 77